SCHEMBL1467336

SCHEMBL1467336

CCCCCNc1ccc(Oc2cccc(S(=O)(=O)NCCCCC)c2)cc1C(=O)OC

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.44
MAPK1 P28482 1/20 0.44
HTT P42858 1/20 0.44
ALDH1A1 P00352 5/20 0.44
MEP1B Q16820 1/20 0.43
PDK1 Q15118 2/20 0.42
PDK2 Q15119 2/20 0.42
PDK3 Q15120 2/20 0.42
PDK4 Q16654 2/20 0.42
PGR P06401 1/20 0.42
TSHR P16473 1/20 0.41
AKR1C3 P42330 2/20 0.41
CA12 O43570 2/20 0.40
CA9 Q16790 2/20 0.40
EPHX2 P34913 1/20 0.40
PKM P14618 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
MMP2 P08253 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1466023 0.87 LMNA (0.45) LMNAMAPK1HTTALDH1A1MEP1B
SCHEMBL1465587 0.83 TDP1 (0.46) LMNAMAPK1HTTALDH1A1CA12
SCHEMBL1465590 0.79 LMNA (0.41) LMNAMAPK1HTTALDH1A1TSHR
SCHEMBL1466020 0.79 LMNA (0.63) LMNAMAPK1HTTALDH1A1MEP1B
SCHEMBL1075649 0.77 AKR1C2 (0.48) LMNA
SCHEMBL1074499 0.77 ALDH1A1 (0.52) LMNAMAPK1HTTALDH1A1TSHR
SCHEMBL1075767 0.77 CACNA1B (0.49) LMNAHTTALDH1A1TSHRPKM
SCHEMBL1465581 0.76 GAA (0.41) LMNAALDH1A1L3MBTL1
SCHEMBL4566591 0.76 CNR2 (0.41) ALDH1A1L3MBTL1
SCHEMBL11157739 0.75 MEP1B (0.59) LMNAMAPK1HTTALDH1A1MEP1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110071197-A1 BIS-ARYL COMPOUNDS FOR USE AS MEDICAMENTS BIOLIPOX AB (LV) 2011-03-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110071197-A1 BIS-ARYL COMPOUNDS FOR USE AS MEDICAMENTS LTC4S, LTB4R2, LTB4R LMNA 710/4885MAPK1 3622/4885HTT 4465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.